In medical news:

An FDA advisory panel could not reach a decision about the best dose for naloxone. The split on whether the injectable 0.4-mg dose should remain the current standard by which products containing the opioid overdose reversal drug should be measured – though they agreed that a lack of data made their decision more challenging. Slightly more panelists voted to increase the minimum acceptable dose rather than maintain it (15-to-13) during the joint meeting of the Anasthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee.

Read complete coverage from MedPage Today here.

Leave a Comment

Your email address will not be published. Required fields are marked *